Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "Human follicle stimulating hormone" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Chr. 11 p13. Follicle-stimulating hormone (FSH) is a gonadotropin, a glycoprotein polypeptide hormone. FSH is synthesized and secreted by the gonadotropic cells of the anterior pituitary gland, and regulates the development, growth, pubertal maturation, and reproductive processes of the body.
Follicle stimulating hormone-glycosylation analogs
InactiveUS20010007757A1Sugar derivativesPeptide/protein ingredientsDimerHuman follicle stimulating hormone
The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc)
ActiveCN103539860AImprove biological activitySmall toxicityPeptide/protein ingredientsAntibody mimetics/scaffoldsRecombinant human follicle stimulating hormoneSide effect
The invention discloses a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) and a preparation method thereof. The recombinant hFSH-Fc is a dimerization fusion protein. An amino acid sequence of the hFSH-Fc comprises an hFSHbeta subunit, CTP (carboxy-terminal peptide), an hFSHalpha subunit, a flexible peptide linker and a human IgG (immunoglobulin G)2 Fc variant from the N terminal to the C terminal in sequence. The hFSH-Fc has longer half-life in vivo and smaller side effects than existing hFSH. The invention also relates to an application of a recombinant hFSH-Fc composition to preparation of drugs for treating and / or preventing infertility.
Owner:UNICOHEALTH CO LTD
Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc)
ActiveCN103539861AImprove biological activityHigh activityPeptide/protein ingredientsPeptide preparation methodsSide effectRecombinant human follicle stimulating hormone
The invention discloses a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) and a preparation method thereof. The hFSH-Fc is a dimerization fusion protein. An amino acid sequence of the hFSH-Fc comprises an hFSHbeta subunit, CTP (carboxy-terminal peptide), an hFSHalpha subunit, a flexible peptide linker and a human IgG (immunoglobulin G) Fc variant from the N terminal to the C terminal in sequence. The hFSH-Fc has longer half-life in vivo and smaller side effects than existing hFSH. The invention also relates to an application of a recombinant hFSH-Fc composition to preparation of drugs for treating and / or preventing infertility.
Owner:UNICOHEALTH CO LTD
Culture method for high-efficiency human follicle stimulating hormone expression CHO cells
ActiveCN105462909AStable batch-to-batch qualityThe cultivation process is stable and controllableMicroorganism based processesVertebrate cellsBottleHigh survival rate
The invention discloses a culture method for high-efficiency human follicle stimulating hormone expression CHO cells and belongs to the technical field of bio-pharmaceuticals. According to the culture method, seed cells are prepared into cell suspension, and subculture is performed after resuspension through a serum-free basal culture medium to obtain seed suspension; the obtained seed suspension is inoculated into a bioreactor to be cultured, the serum-free basal culture medium is fed at regular intervals in the culture process, growth situations of the cells are monitored, glucose solution is supplemented, and the cells are harvested after culture. According to the method, the serum-free basal culture medium is used throughout the process, culture in a fermentation tank is performed after reviving and amplification through bottle shaking, the process flow is simple, the cell culture density is high and can be as high as 4*107 / mL , the cell survival rate reaches more than 98%, maintaining time under high density and a high survival rate is long, the yield of end products can reach 40mg / L, and the method is applicable to industrial production.
Owner:哈药集团股份有限公司 +1
Long-acting recombinant follicle-stimulating hormone and application thereof
ActiveCN103539862AImprove biological activityHigh activityPeptide/protein ingredientsAntibody mimetics/scaffoldsRecombinant human follicle stimulating hormoneHalf-life
The invention discloses a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) and a preparation method thereof. The hFSH-Fc is a dimerization fusion protein. An amino acid sequence of the hFSH-Fc comprises an hFSHbeta subunit, CTP (carboxy-terminal peptide), an hFSHalpha subunit, a flexible peptide linker and a human IgG (immunoglobulin G)2 Fc variant from the N terminal to the C terminal in sequence. The hFSH-Fc has longer half-life in vivo and better efficacy than existing FSH. The invention also relates to an application of a recombinant hFSH-Fc composition to preparation of drugs in the field of animal breeding.
Owner:GUANGZHOU VBIO PHARM CO LTD
Follicle stimulating hormone-glycosylation analogs
The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Method and culture medium for producing human follicle stimulating hormone through high-density perfusion culture of recombinant CHO cells and application of human follicle stimulating hormone
ActiveCN110042137AProlong high-density culture timeReduce cloggingCulture processMicroorganism based processesHollow fibreFiber
The invention discloses a method and culture medium for producing a human follicle stimulating hormone through high-density perfusion culture of recombinant CHO cells and an application of the human follicle stimulating hormone, and belongs to the field of biological pharmacy. The preparation method comprises the steps of after CHO cell recovery, performing cell density amplification with a basicculture medium; after the density of living cells achieves a certain density, performing perfusion culture with a production culture medium; additionally adding a fresh production culture medium to the inner part of a bioreaction tank, trapping the CHO cells with a hollow fiber trapping device connected to the outer part of the reaction tank, so that the cells can maintain high density and vitality; and when the cells in the reactor are in the stable state, starting expression product collection of the CHO cells. Through bioreactor spinner culture and a circumscription cell trapping device, the cells can be trapped, broken slices and expressive protein can be filtered, and high-density environment can be provided for cell growth. Besides, through backward flushing of a hollow fiber column,the fiber plugging is reduced, the high-density culture time of the cells can be prolonged, and the batch yield can be notably increased.
Owner:上海赛迈生物科技有限公司
Long-acting human follicle-stimulating hormone formulation using immunoglobulin fragment
ActiveUS9186415B2Extended half-lifeImprove the level ofPeptide/protein ingredientsPeptide preparation methodsSerum igeHalf-life
The present invention relates to a long-acting human follicle-stimulating hormone formulation having improved in vivo duration and stability, comprising a human follicle-stimulating hormone conjugate that is prepared by covalently linking human follicle-stimulating hormone with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting human follicle-stimulating hormone formulation of the present invention maintains in vivo activity of human follicle-stimulating hormone at a relatively high level and remarkably increases the serum half-life thereof.
Owner:HANMI SCI CO LTD
Method for mass production of human pollicle stimulating hormone
InactiveUS20060223144A1Improve expression levelImprove transcription efficiencyPeptide/protein ingredientsGenetic material ingredientsHormones regulationInfertility
The present invention relates to a method for mass-production of human follicle stimulating hormone, more precisely, to an expression vector containing human follicle stimulating hormone gene, a transformant transfected with the expression vector and a method for mass-production of human follicle stimulating hormone by using the same. Human follicle stimulating hormone can be produced largely by using an expression vector and a transformant of the present invention. Therefore the expression vector and the transformant of the present invention can be effectively used for the treatment of infertility.
Owner:PROGEN CO LTD
Antibodies against the human fshr extracellular domain
ActiveUS20200010556A1High affinityStrong specificityBiological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsExtracellularAntiendomysial antibodies
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
Recombinant human follicle-stimulating hormone and preparation method and drug application thereof
PendingCN111349154AIncrease productionSimple processPeptide preparation methodsDepsipeptidesDimerMedicine
The present invention relates to recombinant human follicle-stimulating hormone and a preparation method and a drug application thereof. The recombinant human follicle-stimulating hormone is rhFSH heterodimer containing alpha and beta chains; for a mammalian cell CHO expression system, optimized design of coding genes is performed; and expression plasmids are constructed in a targeted manner, so that expression and correct combination of the alpha and beta chains of the hFSH in mammalian cells CHO are better facilitated. The rhFSH has the advantages of simple process, high target product yield, high purity, high in vivo activity, convenience for intermediate process control, easiness for large-scale production and the like.
Owner:ZONHON BIOPHARMA INST
Hfsh aqueous formulation
InactiveUS20160243242A1Maintain activityPeptide/protein ingredientsInorganic non-active ingredientsGlycineMedicine
Owner:LG LIFE SCI LTD
Long-acting recombinant human follicle stimulating hormone and preparation method and application thereof
InactiveCN109942717AAssembly has no effectFolding has no effectPeptide/protein ingredientsHybrid peptidesRecombinant human follicle stimulating hormoneHalf-life
The invention provides recombinant hFSH-Fc fusion protein. The fusion protein is dimerized fusion protein, wherein one monomer amino acid sequence sequentially comprises an hFSH beta sub-unit, CTP, CTP and an hFSH alpha sub-unit from the end N to the end C, and the other monomer amino acid sequence sequentially comprises CTP, an hFSH alpha sub-unit, an hFSH beta sub-unit and CTP from the end N tothe end C. The two pieces of CTP are connected to an encoding sequence of an FSH, regions important to receptor binding or bio-activity are avoided, the affinity of receptor binding is not affected, immunogenicity is avoided, and the volume lifetime can be remarkably prolonged. Meanwhile, the in-vivo half-life period of FSH-CTP is longer, the ending half-life period is 2-3 times that of recombinant FSH-WT, one time of injection per week can replace seven times of injection every day, and the bio-activity is higher.
Owner:上海延立生物技术有限公司
Methods and compositions for treating cancer
ActiveUS20170226176A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyChimera ProteinNucleic acid sequencing
A nucleic acid sequence is provided that encodes a chimeric protein comprising a ligand that comprises a naturally occurring or modified follicle stimulating hormone sequence, e.g., an FSHp sequence, or fragment thereof, which ligand binds to human follicle stimulating hormone (FSH) receptor, linked to either (a) a nucleic acid sequence that encodes an extracellular hinge domain, a transmembrane domain, a co-stimulatory signaling region, and a signaling endodomain; or (b) a nucleic acid sequence that encodes a ligand that binds to NKG2D. The vector containing the nucleic acid sequence, the chimeric proteins so encoded, and modified T cells expressing the chimeric protein, as well as method of using these compositions for the treatment of FSHR-expressing cancers or tumor cells are also provided.
Owner:THE WISTAR INST OF ANATOMY & BIOLOGY
Follicular granular cells near-infrared fluorescent probe Nirova-2 as well as preparation method and application thereof
InactiveCN111053922AEasy to prepareImprove stabilityIn-vivo testing preparationsFluoProbesGranular leucocyte
The invention belongs to the technical field of medical imaging contrast agents, and particularly relates to a follicular granular cells near-infrared fluorescent probe Nirova-2 and a preparation method and application thereof. The fluorescent probe provided by the invention is a fluorescent dye-human follicle stimulating hormone coupling complex formed by coupling an organic small molecule near-infrared dye IR800CW and human follicle stimulating hormone (FSH); according to the complex, the fluorescent dye can specifically target granular cells forming follicle walls in ovaries, so that near-infrared fluorescent labeling of all follicles is realized. The fluorescent probe can be used as a near-infrared region fluorescent contrast agent for the follicles in the ovaries by combining the characteristic of fluorescence emission of the IR800CW in a near-infrared region with the property of specific targeted binding of the FSH to the follicle granular cells in the ovaries, so that the numberand the development stage of the follicles in the ovaries of women can be accurately and effectively detected and evaluated.
Owner:FUDAN UNIV
Analytical method for evaluating in-vitro biological activity of human follicle stimulating hormone
InactiveCN104569440AMeet ethical requirementsAvoid harmBiological testingGranular leucocyteOvarian Granulosa Cell
The invention discloses an analytical method of utilizing adherent cell-human ovarian granular cell tumor cell strain (KGN) to evaluate in-vitro biological activity of human follicle stimulating hormone. The method comprises the following steps: using the human follicle stimulating hormone to stimulate the human ovarian granular cell tumor cell, measuring the content of generated progesterone, so as to reflect the activity of the human follicle stimulating hormone. The analytical method of using the human ovarian granular cell tumor adherent cell to evaluate the in-vitro biological activity of the human follicle stimulating hormone, disclosed by the invention, is effective, stable and quick, and avoids the limitations of long time consumption, complicated operation and poor result repeatability in the animal in-vivo ovarian weight increment method; meanwhile, the progesterone content is determined by a commercial enzyme linked immunosorbent assay (ELISA) kit, so that the biological activity of the human follicle stimulating hormone can be reflected truly and more accurately.
Owner:BEIJING TIDE PHARMA
Recombinant human follicle-stimulating hormone and its preparation method
The invention provides a recombinant human follicle-stimulating hormone and a preparation method thereof. Specifically, steps are included: (1) the first expression cassette for expressing FSH α subunit and the second expression cassette for expressing FSH β subunit are operatively inserted into the eukaryotic expression vector to obtain the protein capable of expressing FSH α subunit and the transfection vector of FSH beta subunit protein; (2) transforming the transfection vector into eukaryotic cells, thereby obtaining the transformed eukaryotic cells integrated with the first expression cassette and the second expression cassette in the chromosome; (3) Under conditions suitable for expression, the transformed eukaryotic cells are cultivated to express the FSHα subunit and the FSHβ subunit, thereby obtaining a fermentation product containing recombinant follicle-stimulating hormone; (4) to the described The fermentation product is separated and purified to obtain the recombinant follicle-stimulating hormone. The method of the invention can replace the use and preparation method of the existing human FSH, and obtain rhFSH with significantly improved activity and purity.
Owner:JINGZE PHARMA (HEFEI) CO LTD +2
Long-acting human follicle-stimulating hormone formulation using immunoglobulin fragment
ActiveUS20130022626A1Improve the level ofExtended half-lifePeptide/protein ingredientsAntibody ingredientsSerum igeHalf-life
The present invention relates to a long-acting human follicle-stimulating hormone formulation having improved in vivo duration and stability, comprising a human follicle-stimulating hormone conjugate that is prepared by covalently linking human follicle-stimulating hormone with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting human follicle-stimulating hormone formulation of the present invention maintains in vivo activity of human follicle-stimulating hormone at a relatively high level and remarkably increases the serum half-life thereof.
Owner:HANMI SCI CO LTD
Fibroblast culture medium and preparation method thereof
ActiveCN106635972AProliferate fastRaise the ratioCulture processSkeletal/connective tissue cellsHuman follicle stimulating hormoneTransferrin
The invention relates to a culture medium by which induced pluripotent stem cells are induced into fibroblasts and a preparation method of the culture medium. The culture medium consists of a basic culture solution and an additive, wherein the basic culture solution is a mixture of an H-DMEM culture solution and an F12 culture solution at the volume ratio of 1: (0.5-2); and in terms of concentrations in the basic culture solution, the additive consists of the following components: nonessential amino acid, glutamine derivatives, insulin, hydrocortisone, transferrin, sodium selenite, fibroblast growth factors, estradiol, progestin, 8-bromo cyclophosphate and human follicle stimulating hormone. The culture medium, in comparison with the prior art, is higher than fibroblast differentiation probability; in addition, the culture medium can guarantee stable passage and improve cell propagation speed, so as to offer a fibroblast seed cell source for skin tissue engineering; and meanwhile, the application of serum is avoided in an entire course, so that risks caused by animal-derived pathogens are effectively avoided and the safety of clinical application is enhanced.
Owner:GUANGZHOU RAINHOME PHARM&TECH CO LTD
Hfsh aqueous formulation
InactiveUS20110201554A1Maintain stabilityMaintain activityPeptide/protein ingredientsInorganic non-active ingredientsGlycineMedicine
Provided is an aqueous formulation of a human follicle stimulating hormone (hFSH) which is stabilized to maintain the activity of hFSH for a prolonged period of time. The formulation of the present invention is an aqueous formulation comprising a therapeutically effective amount of hFSH stabilized in a phosphate buffer containing glycine, methionine and a non-ionic surfactant, preferably polysorbate 20, which is capable of maintaining the activity of hFSH for an extended period of time.
Owner:LG LIFE SCI
Long-acting recombinant FSH fusion protein, preparation method thereof and application of long-acting recombinant FSH fusion protein to timing semen deposition of sows
InactiveCN110041434AProlong half-life in vivoPromote estrus synchronizationPolypeptide with localisation/targeting motifPeptide/protein ingredientsHalf-lifeHormones regulation
The invention discloses long-acting recombinant FSH fusion protein, a preparation method thereof and an application of the long-acting recombinant FSH fusion protein to timing semen deposition of sows. The long-acting recombinant FSH fusion protein comprises human follicle-stimulating hormone Fc fusion protein (hFSH-Fc), porcine follicle-stimulating hormone Fc fusion protein (pFSH-Fc), human follicle-stimulating hormone follicle hormone CTP fusion protein(hFSH-CTP) and porcine follicle-stimulating hormone CTP fusion protein (pFSH-CTP). The long-acting recombinant FSH fusion protein can notablyprolong the half-life in vivo of protein, can notably induce synchronous development of ovarian follicle after being used for multiparous sows and replacement sows, and can promote synchronous estrusof the sows when being used in timing semen deposition procedure of the replacement sows and the multiparous sows, and can also notably increase the estrus rate, the total conception rate and the number born per litter for the sows.
Owner:GUANGZHOU VBIO PHARM CO LTD
A kind of culture method of cho cell expressing human follicle-stimulating hormone highly
ActiveCN105462909BStable batch-to-batch qualityThe cultivation process is stable and controllableMicroorganism based processesArtificial cell constructsHigh survival rateBottle
Owner:哈药集团股份有限公司 +1
Long-acting recombinant follicle-stimulating hormone and application thereof
ActiveCN103539862BProlong half-life in vivoImprove mechanical propertiesPeptide/protein ingredientsAntibody mimetics/scaffoldsProtein compositionIn vivo
The invention discloses a long-acting recombinant human follicle-stimulating hormone fusion protein (Human follicle-stimulating hormone-Fc fusion protein, referred to as hFSH-Fc) and a preparation method thereof. The hFSH-Fc protein is a dimerization fusion protein, and its amino acid The sequence from N-terminal to C-terminal includes hFSHβ subunit, CTP, hFSHα subunit, flexible peptide linker and human IgG2Fc variant. Its in vivo half-life is longer than that of existing follicle-stimulating hormone and its drug effect is better. The invention also relates to the use of the recombinant hFSH-Fc fusion protein composition in the preparation of medicines in the field of animal reproduction.
Owner:GUANGZHOU VBIO PHARM CO LTD
Recombinant CHO cell strain with high expression of human follicle stimulating hormone and construction method thereof
PendingCN113512537AHigh expressionQuality improvementGenetically modified cellsDepsipeptidesProtein targetPregnancy
The invention relates to the technical field of auxiliary devices of a pregnancy assisting technology, in particular to a recombinant CHO cell strain with high expression of human follicle stimulating hormone and a construction method thereof. The recombinant CHO cell strain is high in purity, low in cost and stable in biological activity, and comprises a CHO-S cell strain, a pCHO1.0 vector, a high expression element and a target protein amino acid sequence.
Owner:长春生物制品研究所有限责任公司
Recombinant human follicle stimulating hormone and preparation method thereof
PendingCN112195194AEfficient captureEfficient removalPeptide preparation methodsNucleic acid vectorRecombinant human follicle stimulating hormoneCricetulus
The invention discloses a recombinant human follicle stimulating hormone and a preparation method thereof. The preparation method comprises the following steps: jointly transfecting a constructed expression vector containing an FSHalpha subunit and an expression vector containing an FSHbeta subunit into Chinese hamster ovary cells, screening out stably expressed cell strains, and purifying and culturing the cell strains to obtain a culture solution, thereby obtaining the recombinant human follicle stimulating hormone, wherein the C-terminus of the FSHbeta subunit is connected with CTP. According to the preparation method of the recombinant human follicle stimulating hormone, hFSHalpha and hFSHbeta sequences comprising introns are cloned from human embryonic kidney 293 cell genomes respectively, CTP sequences are connected to the terminus of the beta subunit in a primer extension mode to obtain hFSHbeta-CTP, then the two subunit sequences are transfected to CHO-S cells, rhFSH-CTP is obtained through expression, the half-life period of the rhFSH-CTP obtained by expression in vivo is longer, the final half-life period is 2-3 times that of recombinant FSH, and the biological activity is higher.
Owner:北京双鹭生物技术有限公司 +2
Fibroblast culture medium and preparation method thereof
ActiveCN106635972BProliferate fastRaise the ratioCulture processSkeletal/connective tissue cellsPluripotential stem cellHydrocortisone
The invention relates to a culture medium by which induced pluripotent stem cells are induced into fibroblasts and a preparation method of the culture medium. The culture medium consists of a basic culture solution and an additive, wherein the basic culture solution is a mixture of an H-DMEM culture solution and an F12 culture solution at the volume ratio of 1: (0.5-2); and in terms of concentrations in the basic culture solution, the additive consists of the following components: nonessential amino acid, glutamine derivatives, insulin, hydrocortisone, transferrin, sodium selenite, fibroblast growth factors, estradiol, progestin, 8-bromo cyclophosphate and human follicle stimulating hormone. The culture medium, in comparison with the prior art, is higher than fibroblast differentiation probability; in addition, the culture medium can guarantee stable passage and improve cell propagation speed, so as to offer a fibroblast seed cell source for skin tissue engineering; and meanwhile, the application of serum is avoided in an entire course, so that risks caused by animal-derived pathogens are effectively avoided and the safety of clinical application is enhanced.
Owner:GUANGZHOU RAINHOME PHARM&TECH CO LTD
Human follicle-stimulating hormone receptor (FSHR) extracellular domain antibodies and methods of use thereof
ActiveUS10927179B2Effectively andSure easyBiological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesCancer cell
Owner:FSHR THERANOSTICS SAS
Double-antibody sandwich enzyme-linked immunoassay method for quantitatively detecting human follicle-stimulating hormone
InactiveCN107490700AStrong specificityEasy to operateBiological testingHair follicleSystem stability
The invention provides a double-antibody sandwich enzyme-linked immunoassay method for quantitatively detecting human follicle-stimulating hormone (hFSH). The invention mainly aims to solve the technical problems of low sensitivity, low system stability, limited detection scope, low repeatability, complex operation, and the like, in the prior art. According to the invention, two paired specific monoclonal antibodies (namely, anti-FSH alpha antibody and anti-FSH beta antibody) are adopted for detecting and quantizing human follicle-stimulating hormone or related follicle-stimulating hormone sample. The method provided by the invention has the advantages of easy operation, high sensitivity, high specificity, high system stability, wide FSH detection scope and capability of directly reflecting the concentration or in vitro biologic activity of an FSH standard substance or sample according to a light absorption value (OD value) detected by a microplate reader.
Owner:JIANGXI SCI & TECH NORMAL UNIV
Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc)
ActiveCN103539860BProlong half-life in vivoImprove mechanical propertiesPeptide/protein ingredientsAntibody mimetics/scaffoldsPharmaceutical drugHuman follicle stimulating hormone
Owner:UNICOHEALTH CO LTD
Application of long-acting recombinant FSH (follicle-stimulating hormone) fusion protein to batch production of sows
InactiveCN110041436AProlong half-life in vivoIncrease estrus ratePolypeptide with localisation/targeting motifPeptide/protein ingredientsHalf-lifeLitter
The invention discloses an application of long-acting recombinant FSH (follicle-stimulating hormone) fusion protein to batch production of sows. The long-acting recombinant FSH fusion protein comprises human follicle-stimulating hormone Fc fusion protein (hFSH-Fc), porcine follicle-stimulating hormone Fc fusion protein (pFSH-Fc), human follicle-stimulating hormone CTP fusion protein (hFSH-CTP) andporcine follicle-stimulating hormone CTP fusion protein (pFSH-CTP). The recombinant FSH fusion protein can notably prolong the in vivo half-life of protein; when the recombinant FSH fusion protein isused for multiparity sows and replacement sows, synchronous development of ovarian follicle can be induced; when the long-acting recombinant FSH fusion protein is used for batch production of the sows, the synchronous oestrus of the sows can be notably promoted, the oestrus rate, the total conception rate, the total delivery rate and the number born per litter of the replacement sows and the multiparity sow can be notably increased, and the reproductive performance of the sows can be notably increased.
Owner:GUANGZHOU VBIO PHARM CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com